Letaplimab represents a unique clinical method for treating complement-mediated diseases. This antibody targets complement component C1q, a essential component of the complement cascade, aiming to inhibit its early https://alyshaffoc711737.aboutyoublog.com/52729372/letaplimab-a-groundbreaking-therapeutic-strategy